Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 26Active not recruiting 14Unknown 9Terminated 8Recruiting 4Not yet recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Breast Neoplasms 3Endometrial Neoplasms 2Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Oligometastatic Prostate Carcinoma 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Endometrial Hyperplasia 1Anatomic Stage III Breast Cancer AJCC v8 1Advanced Breast Cancer 1

Interventions

Magnetic Resonance Spectroscopy 51Specimen Handling 42enzalutamide 36Androgen Antagonists 35Radiosurgery 33Radiotherapy 31darolutamide 26Prednisone 26Abiraterone Acetate 25Leuprolide 22Docetaxel 22apalutamide 21abiraterone 19Pluvicto 19Standard of Care 18Triptorelin Pamoate 17Radiation 17Biopsy 16relugolix 15acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 14Blood Specimen Collection 13gallium 68 PSMA-11 12X-Rays 11Surveys and Questionnaires 11pembrolizumab 10luprolide acetate gel depot 10Carboplatin 10Methods 9Interviews as Topic 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms × Gonadotropin-Releasing Hormone × Clear all
NCT07142551 2026-03-11

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT05498272 2026-01-23

NePtune

Hoosier Cancer Research Network

Phase 2 Recruiting
32 enrolled
Genitourinary

Prostatic Neoplasms

NCT06059118 2026-01-14

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT06922318 2025-09-17

The COSMYC Trial (COmbined Suppression of MYC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡